Lexaria Bioscience -CW25LEXXWPreferred / convertible
13F holders, Q1 2025 (March 31)2holders −1
0new positions
1sold out
$0.33avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Lexaria Bioscience -CW25 (LEXXW) in their 13F filings, down 1 from Q4 2024. 0 opened new positions and 1 sold out. The largest holders were Heights Capital Management, Inc. ($13K) and UBS Group AG ($2K).
- Company
- Lexaria Bioscience -CW25
- CUSIP
- 52886N117
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $76 |
All 13F filers, Q4 2024 → Q1 2025: 1,084 shares sold, net −1,084 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Heights Capital Management, Inc. | — | No change | 41,251 | $13K |
| UBS Group AG | — | Reduce -19.0% | 4,195 | $2K |
"% of holder's portfolio" is LEXXW's weight in each manager's 13F, not the share of Lexaria Bioscience -CW25 the manager owns.